Searchable abstracts of presentations at key conferences in endocrinology

ea0029p361 | Clinical case reports - Pituitary/Adrenal | ICEECE2012

Familial isolated pituitary adenoma cases in Hungary

Denes J. , Kovacs G. , Patocs A. , Glaz E. , Mezosi E. , Hubina E. , Kovacs L. , Gorombey Z. , Czirjak S. , Korbonits M. , Goth M.

Familial isolated pituitary adenoma (FIPA) occurs if two or more members of a family develop pituitary adenoma with no features of multiple endocrine neoplasia type 1 or Carney complex. FIPA is an autosomal dominant disease with incomplete penetrance. FIPA families can be divided into two distinct groups based on genetic and phenotypic features. In 20% of FIPA families mutations have been identified in the aryl hydrocarbon receptor interacting protein (AIP) gene. The AIP-posit...

ea0028p236 | Pituitary | SFEBES2012

Evaluation of the expression of vesicular protein (SNARE) isoforms in human pituitary adenomas

Garcia Edwin , Trivellin Giampaolo , Michael Powell , Grieve Joan , Sabin Ian , Alusi Ghassan , Louis Pobereskin , Shariati Babak , Roncaroli Federico , Mendoza Nigel , Grossman Ashley , Harper Elaine , Korbonits Marta

Background: Botulinum neurotoxin inhibits muscle function by interfering with neurotransmitter release from secretory vesicles. The mechanism underlying this effect involves cleavage of SNARE proteins which are required for vesicle docking at the plasma membrane. The ability of botulinum neurotoxin serotypes to cleave SNARE proteins and inhibit secretion is being exploited for therapeutic purposes by Syntaxin Ltd with their ‘targeted secretion inhibitor technology’ (...

ea0021oc2.4 | Neuroendocrine tumours/pituitary | SFEBES2009

Geographical cluster of familial isolated pituitary adenoma kindreds with an identical AIP mutation

Ozfirat Zehra , Cain Josh , Chahal Harvinder , Stals Karen , Ellard Sian , Howlett Trevor , Levy Miles , Atkinson Brew , Morrison Patrick , Akker Scott , Grossman Ashley , Korbonits Marta

Mutations in the co-chaperone molecule AIP account for a predisposition to pituitary tumours in some families with familial isolated pituitary adenomas (FIPA). We now report on four apparently-unrelated families with the same mutation and originating from the same geographical area, suggesting a possible founder mutation.The index patient had gigantism (19 years, 208 cm) and had a female 4th cousin, once removed (13 years, 191 cm) with a large pituitary ...

ea0015oc2 | Young Endocrinologist prize session | SFEBES2008

The ghrelin-cannabinoid axis: a novel pathway in the regulation of appetite and metabolism

Amin Faisal , Kola Blerina , Christ-Crain Mirjam , Lolli Francesca , Wittmann Gabor , Harvey-White Judith , Kunos George , Grossman Ashley B , Fekete Csaba , Korbonits Marta

We have previously shown that the orexigenic and peripheral adipogenic effects of ghrelin are mediated by its effect on the metabolic enzyme AMPK. As the cannabinoid (CB1)-antagonist rimonabant inhibits the orexigenic effect of ghrelin, we suggest that there is an interaction between cannabinoids and ghrelin.To study the involvement of CB1 in the effects of ghrelin, wild-type (WT) and CB1-knockout mice were treated with ghrelin and rimonabant.<p clas...

ea0014p605 | (1) | ECE2007

Familial acromegaly – the role of the AIP gene

Gueorguiev M , Lolli F , Chapple JP , Quinton R , Ribeiro-de-Oliveira A , Gadelha MR , Popovic V , Monson JP , Wass JAH , Frohman LA , Grossman AB , Korbonits M

Pituitary adenomas are present in ∼25% of autopsy samples, and recent studies have also suggested that clinically important pituitary adenomas are some 5 times more common than previously recognised. Acromegaly is almost always due to a sporadic growth-hormone secreting pituitary adenoma, but familial acromegaly has been reported occasionally. Linkage and loss of heterozygosity studies have shown that it is caused by a tumour suppressor gene located at 11q13; very recent...

ea0056p1160 | Thyroid cancer | ECE2018

Treatment strategies in medullary thyroid carcinoma – outcome following initial surgery with a curative, debulking or prophylactic intent

Mitravela Vasiliki-Ioanna , Glynn Nigel , Waterhouse Mona , Akker Scott , Korbonits Marta , Drake William , Berney Daniel , Plowman Nick , Carpenter Robert , Parvanta Laila , Druce Maralyn

Medullary thyroid carcinoma (MTC) is a rare malignancy which has often metastasised at time of diagnosis. Surgical resection represents the only prospect for cure. However, debulking neck surgery may be beneficial in advanced cases. Prophylactic surgery is increasingly undertaken in asymptomatic patients with known mutations in the RET oncogene. The aim was to describe the outcome following initial surgical treatment for MTC at our institution. We performed a retrospe...

ea0073aep488 | Pituitary and Neuroendocrinology | ECE2021

Pituitary surgery in northern ireland: A twenty year retrospective population based analysis

Loughrey Paul Benjamin , Craig Stephanie , Herron Brian , Cooke Stephen , Weir Philip , Bhattacharya Debarata , Sturdy Erin , Salto-Tellez Manuel , Parkes Eileen , McArt Darragh , Korbonits Marta , Hunter Steven , James Jacqueline

In Northern Ireland, the sole tertiary referral centre for pituitary disease which includes neurosurgery and endocrinology for ~1.9 million people, is based in the Royal Victoria Hospital, Belfast. A retrospective study has been commenced to examine clinical, biochemical, histopathological and radiological data for all patients operated on across an approximately 20 year period in Northern Ireland. Ethical approval was obtained from the Northern Ireland Biobank (study num...

ea0094p363 | Neuroendocrinology and Pituitary | SFEBES2023

Hindering the progression of cardiac fibrosis in acromegaly – the role of somatostatin receptor ligands

Sanpawithayakul Kanokporn , Mistry Anisha , Rai Ashutosh , Funge Gregory , Sebastian Sonia , Solomou Antonia , Lillina Vignola Maria , Gaston-Massuet Carles , Tinker Andrew , Begalli Federica , Korbonits Marta

Introduction: Acromegaly links to cardiomyopathy and potential cardiac failure, if untreated. Mechanisms involved in acromegalic cardiomyopathy are incompletely understood. We investigated the effects of growth hormone (GH) excess and somatostatin receptor ligands (SRLs) on cardiac fibrosis using an acromegalic mouse model with pituitary-specific deletion of the Aip gene coding aryl hydrocarbon receptor interacting protein (AipFlox/Flox;Hesx1<su...

ea0077p92 | Neuroendocrinology and Pituitary | SFEBES2021

Age- gender- and tanner stage-specific reference intervals for serum insulin-like growth factor binding protein 3 (IGFBP-3) and the insulin-like growth factor I (IGF-I) to IGFBP-3 molar ratios in healthy school children of a north indian city

Ravi Teja KV , Marwaha RK , Malhotra Bhanu , Sachdeva Naresh , Das Liza , Rastogi Ashu , Mukherjee Soham , Sharma Sadhna , Verma Neelam , Malhotra Sunita , Bhansali Anil , Bhadada Sanjay , Pal Rimesh , G Dewan , Monaghan Phillip , Trainer Peter , Korbonits Marta , Dutta Pinaki

Context: Serum IGF-binding protein-3 (IGFBP-3) and molar IGF-I to IGFBP-3 ratio can aid the diagnosis of GH-related diseases. However, their clinical utility is limited by lack of validated reference intervals.Objectives: To establish age-, gender- and Tanner stage-specific reference intervals for IGFBP-3 and IGF-I to IGFBP-3 ratio for Indian ethnicity.Setting and Participants: We conducted a cross-sectional epidemiological study (...

ea0077p212 | Neuroendocrinology and Pituitary | SFEBES2021

Cabergoline treatment in human primary non-functioning pituitary adenomas

Begalli Federica , Komagata Tatsuya , Suleyman Oniz , Magid Kesson , Rice Thomas , Collier David , Dorward Neil , Grieve Joan , Mendoza Nigel , Nair Ramesh , Kolias Angelos , Khan Danyal , Marcus Hani J , Botta Joaquin , McCormick Peter J , Shinozaki Koji , Korbonits Marta

Non-functioning pituitary adenomas (NFPAs) are the second most common subtype (15-43%) of all clinically presenting pituitary adenomas. Although the primary treatment of symptomatic NFPAs is surgery, gross total resection is achieved only in about 66% of the cases, and 20% of gross total resected tumours recur after 10 years. Despite recent advances in medical management of pituitary tumours, NFPAs remain the only subtype with no widely accepted pharmacological treatment. Expr...